Phase 2 crossover RCT in 21 adults with acute chronic spontaneous urticaria flares: epinephrine nasal spray (ARS-2, 1 or 2 mg) lowered patient-reported hive and itch scores and investigator-rated extent vs placebo; only minor adverse events.
RCTn = 21
Bernstein et al. Efficacy of Epinephrine Nasal Spray in the Treatment of Urticaria